When was Sernova founded?

Sernova was founded in 1998 and raised its 1st funding round 3 years after it was founded.

Where is Sernova located?

Sernova is headquartered in London, Canada.

How many employees does Sernova have?

As of Jul 31, 2026, the latest employee count at Sernova is 20.

Is Sernova a funded company?

Sernova is a funded company, having raised an undisclosed amount across 28 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Feb 26, 2001.

When was the latest funding round of Sernova?

Sernova's latest funding was a $***** Post IPO round on Oct 31, 2025, with participation from 0 investor. Its primary sector is Metabolic Diseases. In Canada, the Metabolic Diseases sector has seen $39.5M in funding in 2026 to date.

Where does Sernova rank among its competitors?

Sernova ranks 8th amongst 82 active competitors, of which 27 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Enlivex Pharmaceuticals, which secured $212M in Nov, 2025.

Who are the top competitors of Sernova?

Sernova's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept. Among them, Enlivex Pharmaceuticals secured the most recent funding round in November, 2025.

Sernova - 2026 Company Profile, Team, Funding & Competitors

Sernova is a public company based in London (Canada), founded in 1998. It operates as a Regenerative medicine to deliver proteins and hormones for disease treatment. Sernova has raised an undisclosed amount in funding. The company has 82 active competitors, including 27 funded and 31 that have exited. Its top competitors include companies like Rhythm Pharmaceuticals, MannKind Corp and Corcept.

Company Details

Sernova Corp. is a development stage regenerative medicine company. The Company is focused on commercializing the Cell Pouch, a scalable, implantable, medical device for the transplantation and survival of therapeutic cells, which then release proteins and hormones for the long-term treatment of various diseases, such as diabetes, hemophilia and thyroid disease. The Company is also developing Sertolin, a cell-based technology providing an immune-privileged environment for donor cells, reducing or eliminating the need for anti-rejection drugs. The Company's primary program is the clinical development of the Cell Pouch for the treatment of patients with insulin-dependent diabetes.

Website: sernova.com
Social

Key Metrics

Founded Year

1998

Location

London, Canada

Stage

Public

Latest Funding Round

Post IPO, Oct 31, 2025, $*****

Investors

National Research Council Canada & 2 more

Ranked

8^th among 82 active competitors

Employee Count

20 as on Jul 31, 2026

Similar Companies

Rhythm Pharmaceuticals & 110 more

Exit Details

Public

View Sernova's full profile

Sernova got listed on Jun 02, 2022.

Click here to take a look at Sernova's IPO in detail

Sernova has raised funding over 28 rounds. Its first funding round was on Feb 26, 2001. Sernova has 3 institutional investors.

Here is the list of recent funding rounds of Sernova:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 31, 2025	7514080	Post IPO	5312043	8633445	1337562	3564526
Mar 04, 2025	6735235	Post IPO	1894033	6261964	1359309	7992693
Sep 03, 2024	6507135	Post IPO	1110789	5670382	3457899	7410084

Access funding benchmarks and valuations. Sign up today!

View details of Sernova's funding rounds and investors

Sernova's employee count trend

Sernova has 20 employees as of Jul 26. Here is Sernova's employee count trend over the years:

Uncover Sernova's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sernova include Rhythm Pharmaceuticals, MannKind Corp and Corcept. Here is the list of Top 10 competitors of Sernova, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	70/100
3rd	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Longitude Capital, BioBrit & 7 others	68/100
4th	Beta Bionics 2015, Boston (United States), Public	Innovating diabetes management with automated bionic pancreas technology	$349M	Eventide Asset Management, Perceptive Advisors ... & 19 others	67/100
5th	Enlivex Pharmaceuticals 2005, Jerusalem (Israel), Public	Developer of autologous and allogeneic cell immunotherapy therapy treatments	$7M	Pontifax, Korea Investment Holdings & 2 others	62/100
6th	Genfit 1999, Loos (France), Public	Therapeutics for cardiometabolic and neurodegenerative diseases.	-	Eiffel Investment Group, Ridgeback Capital Management ... & 2 others	59/100
7th	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	Longitude Capital, Orbimed & 3 others	58/100
8th	Sernova 1998, London (Canada), Public	Regenerative medicine to deliver proteins and hormones for disease treatment	-	National Research Council Canada, Evotec & 1 others	57/100
9th	Verdiva Bio 2024, London (United Kingdom), Series A	Developer of oral and injectable peptide therapies for metabolic diseases	$411M	General Atlantic, Forbion & 5 others	56/100
10th	Orgenesis 2008, Germantown (United States), Public	Developer of cell and gene therapies for multiple disorders	-	Kodiak Capital, Metalmark Capital & 4 others	55/100